<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04980092</url>
  </required_header>
  <id_info>
    <org_study_id>ROPS</org_study_id>
    <nct_id>NCT04980092</nct_id>
  </id_info>
  <brief_title>Assessment of Kidney Function and Osteomuscular Status After Critical Care</brief_title>
  <official_title>Assessment of Kidney Function and Osteomuscular Status in Survivors of a Prolonged Stay in Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study aims to assess kidney function through direct glomerular filtration&#xD;
      rate (GFR) using iohexol clearance, compared to estimated GFR based on creatinine and&#xD;
      cystatin C equations. Kidney function will also be evaluated through renal fibrosis&#xD;
      biomarkers. Kidney function will be correlated to body composition, muscle turnover&#xD;
      biomarkers, and bone micro-architecture.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators developed a post-ICU clinic where complications of the post-intensive care&#xD;
      syndrome are detected. Muscle function is assessed by clinical testings, muscle strength&#xD;
      measurement. Body composition is measured by electrical bioimpedance. Bone mass is assessed&#xD;
      using dual-energy radiographic absorptiometry.&#xD;
&#xD;
      It is well known that ICU survivors experience a loss of muscle mass. This can lead to&#xD;
      misinterpretation of estimated GFR based on creatinine equations.&#xD;
&#xD;
      The aim of the present study is to assess the evolution of kidney function after a prolonged&#xD;
      stay in ICU, using GFR equations based on cystatin C, and to compare it to measured GFR using&#xD;
      iohexol clearance.&#xD;
&#xD;
      The second aim is to explore the evolution of bone and muscle health in these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>measured GFR</measure>
    <time_frame>between day 0 and day 7 after ICU discharge</time_frame>
    <description>plasma clearance of iohexol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measured GFR</measure>
    <time_frame>at 3 months after ICU discharge</time_frame>
    <description>plasma clearance of iohexol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measured GFR</measure>
    <time_frame>at 12 months after ICU discharge</time_frame>
    <description>plasma clearance of iohexol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>estimated GFR</measure>
    <time_frame>between day 0 and day 7 after ICU discharge</time_frame>
    <description>cystatin C based CKD-EPI equation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>estimated GFR</measure>
    <time_frame>at 3 months after ICU discharge</time_frame>
    <description>cystatin C based CKD-EPI equation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>estimated GFR</measure>
    <time_frame>at 12 months after ICU discharge</time_frame>
    <description>cystatin C based CKD-EPI equation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>between day 0 and day 7 after ICU discharge</time_frame>
    <description>urine measurement of TGF-β concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>at 3 months after ICU discharge</time_frame>
    <description>urine measurement of TGF-β concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>at 12 months after ICU discharge</time_frame>
    <description>urine measurement of TGF-β concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>between day 0 and day 7 after ICU discharge</time_frame>
    <description>urine measurement of monocyte chemoattractant protein-1 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>at 3 months after ICU discharge</time_frame>
    <description>urine measurement of monocyte chemoattractant protein-1 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>at 12 months after ICU discharge</time_frame>
    <description>urine measurement of monocyte chemoattractant protein-1 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>between day 0 and day 7 after ICU discharge</time_frame>
    <description>urine measurement of matrix metalloproteinases concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>at 3 months after ICU discharge</time_frame>
    <description>urine measurement of matrix metalloproteinases concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>at 12 months after ICU discharge</time_frame>
    <description>urine measurement of matrix metalloproteinases concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>between day 0 and day 7 after ICU discharge</time_frame>
    <description>urine measurement of chemokine ligands concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>at 3 months after ICU discharge</time_frame>
    <description>urine measurement of chemokine ligands concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>at 12 months after ICU discharge</time_frame>
    <description>urine measurement of chemokine ligands concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>between day 0 and day 7 after ICU discharge</time_frame>
    <description>urine measurement of C-X-C motif chemokine ligand concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>at 3 months after ICU discharge</time_frame>
    <description>urine measurement of C-X-C motif chemokine ligand concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>at 12 months after ICU discharge</time_frame>
    <description>urine measurement of C-X-C motif chemokine ligand concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>between day 0 and day 7 after ICU discharge</time_frame>
    <description>measurement of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>at 3 months after ICU discharge</time_frame>
    <description>measurement of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine concentration of renal fibrose biomarkers</measure>
    <time_frame>at 12 months after ICU discharge</time_frame>
    <description>measurement of proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of muscle turnover markers</measure>
    <time_frame>between day 0 and day 7 after ICU discharge</time_frame>
    <description>blood measurement of myostatin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of muscle turnover markers</measure>
    <time_frame>at 3 months after ICU discharge</time_frame>
    <description>blood measurement of myostatin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of muscle turnover markers</measure>
    <time_frame>at 12 months after ICU discharge</time_frame>
    <description>blood measurement of myostatin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of muscle turnover markers</measure>
    <time_frame>between day 0 and day 7 after ICU discharge</time_frame>
    <description>blood measurement of procollagen type III N-terminal peptide (P3NP) concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of muscle turnover markers</measure>
    <time_frame>at 3 months after ICU discharge</time_frame>
    <description>blood measurement of procollagen type III N-terminal peptide (P3NP) concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of muscle turnover markers</measure>
    <time_frame>at 12 months after ICU discharge</time_frame>
    <description>blood measurement of procollagen type III N-terminal peptide (P3NP) concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of muscle turnover markers</measure>
    <time_frame>between day 0 and day 7 after ICU discharge</time_frame>
    <description>blood measurement of insulin growth factor 1 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of muscle turnover markers</measure>
    <time_frame>at 3 months after ICU discharge</time_frame>
    <description>blood measurement of insulin growth factor 1 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of muscle turnover markers</measure>
    <time_frame>at 12 months after ICU discharge</time_frame>
    <description>blood measurement of insulin growth factor 1 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone micro-architecture</measure>
    <time_frame>between day 0 and day 7 after ICU discharge</time_frame>
    <description>high resolution peripheral quantitative computed tomography (HRpQCT) images acquisition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone micro-architecture</measure>
    <time_frame>at 3 months after ICU discharge</time_frame>
    <description>high resolution peripheral quantitative computed tomography (HRpQCT) images acquisition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone micro-architecture</measure>
    <time_frame>at 12 months after ICU discharge</time_frame>
    <description>high resolution peripheral quantitative computed tomography (HRpQCT) images acquisition</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Critical Illness</condition>
  <condition>Kidney Injury</condition>
  <condition>Muscle Loss</condition>
  <condition>Bone Loss</condition>
  <arm_group>
    <arm_group_label>Post-ICU group</arm_group_label>
    <description>Observational foolow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>one-year follow-up</intervention_name>
    <description>patients will be followed during the year after ICU discharge, in order to assess kidney function, and muscle and bone health</description>
    <arm_group_label>Post-ICU group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        survivors of an ICU stay of at least 7 days&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients surviving an ICU stay of at least 7 days&#xD;
&#xD;
          -  patients who experienced acute kidney injury (KDIGO criteria) during ICU stay&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic kidney injury with dedicated follow-up before ICU admission&#xD;
&#xD;
          -  chronic extrarenal epuration&#xD;
&#xD;
          -  kidney transplant&#xD;
&#xD;
          -  allergy to iohexol&#xD;
&#xD;
          -  iodinated contrast allergy&#xD;
&#xD;
          -  refusal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Françoise Rousseau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Liège</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Françoise Rousseau, MD, PhD</last_name>
    <phone>+3243667495</phone>
    <email>afrousseau@chuliege.be</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 17, 2021</last_update_submitted>
  <last_update_submitted_qc>July 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Anne-Françoise Rousseau</investigator_full_name>
    <investigator_title>Head of Clinic</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

